Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.31 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.30 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20890572 | 0.84 | MAP4K1 (0.36) | CYP1A2POLBHCRTR1HCRTR2 | |
| SCHEMBL23190388 | 0.84 | KDM4E (0.39) | HCRTR1HCRTR2NOS3NOS2NOS1 | |
| SCHEMBL31691992 | 0.84 | IDH1 (0.33) | CYP1A2POLBHCRTR1HCRTR2 | |
| SCHEMBL13891753 | 0.84 | CYP1A2 (0.33) | CYP1A2POLBHCRTR1HCRTR2 | |
| SCHEMBL18501682 | 0.82 | NUDT1 (0.33) | ADORA2AADORA1SYKNUDT1 | |
| SCHEMBL8171795 | 0.82 | IDH1 (0.42) | CYP1A2POLB | |
| SCHEMBL12341062 | 0.82 | CCR1 (0.39) | ADORA2AADORA1HCRTR1HCRTR2SYK | |
| SCHEMBL12247034 | 0.80 | KCNH2 (0.41) | ADORA2AADORA1HCRTR1HCRTR2 | |
| SCHEMBL21325018 | 0.79 | NUDT1 (0.34) | CYP1A2ADORA2AADORA1HCRTR1HCRTR2 | |
| SCHEMBL20618609 | 0.79 | NOS3 (0.37) | ADORA2AADORA1NOS3NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20220223796-A1 | ORGANIC COMPOUND, ELECTRONIC COMPONENT CONTAINING ORGANIC COMPOUND, AND ELECTRONIC DEVICE | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9073907-B2 | Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | BOLEA CHRISTELLE (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-20110076387-A1 | METHOD FOR IMPARTING ANTIBIOTIC ACTIVITY TO THE SURFACE OF A SOLID SUBSTRATE | LONZA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-11-13 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | HDAC1, CDK9, CDK2 | CYP1A2 2686/4885POLB 197/4885ADORA2A 3693/4885 |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | CYP1A2 4279/4885POLB 76/4885ADORA2A 1132/4885 |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | CYP1A2 2697/4885POLB 4593/4885ADORA2A 115/4885 |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CYP1A2 55/4885POLB 4041/4885ADORA2A 330/4885 |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | CYP1A2 250/4885POLB 2896/4885ADORA2A 932/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | CYP1A2 3975/4885POLB 2427/4885ADORA2A 2254/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | CYP1A2 2243/4885POLB 4032/4885ADORA2A 3184/4885 |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | TUBB6, MAN2B1, TUBB1 | CYP1A2 4823/4885POLB 1904/4885ADORA2A 4858/4885 |
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | TUBB6, TUBB1, TUBA1C | CYP1A2 4837/4885POLB 2018/4885ADORA2A 4874/4885 |
| US-20220223796-A1 | ORGANIC COMPOUND, ELECTRONIC COMPONENT CONTAINING ORGANIC COMPOUND, AND ELECTRONIC DEVICE | EXOC1, EXOC4, CHRM1 | CYP1A2 350/4885POLB 1029/4885ADORA2A 2336/4885 |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | CYP1A2 2142/4885POLB 38/4885ADORA2A 1188/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | CYP1A2 247/4885POLB 560/4885ADORA2A 3818/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP1A2 2142/4885POLB 38/4885ADORA2A 1188/4885 |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM4, GRM1 | CYP1A2 2969/4885POLB 4484/4885ADORA2A 81/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | CYP1A2 247/4885POLB 560/4885ADORA2A 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.